The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>
 
Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).

More >>
 
Dr. Elizabeth Eisenhauer by Bernard Clark

Dr. Elizabeth Eisenhauer presented with 2021 Canada Gairdner Wightman Award

Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.

More >>
 

MAC15 RxPONDER trial presented at the San Antonio Breast Cancer Symposium

Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.

More >>
 

Planned trials

CLC3

Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

More >>

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

I240

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

More >>

MA41

De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

MAC27

COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

MYC2

Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration

More >>

Recently activated

CO29

Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)

More >>

CXC2

Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

More >>

SR7

Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

More >>

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

New pancreatic cancer trial provides hope to BC family

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma (ONLINE)

Eur J Haematol n/a, 2021
Monteith BE;Venner CP;Cheung MC;Pater J;Shepherd L;Richardson H;Reece D;Gul E;Lalancette M;Castonguay V;Kukreti V;Tiedemann R;Phua C;Bhella S;Dudebout J;Sherry M;Yen H;Chen BE;Hay AE;

More >>

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

npj Breast Cancer 7: 74, 2021
Goodwin PJ;Dowling RJO;Ennis M;Chen BE;Parulekar WR;Shepherd LE;Burnell MJ;Vander Meer R;Molckovsky A;Gurjal A;Gelmon KA;Ligibel JA;Hershman DL;Mayer IA;Whelan TJ;Hobday TJ;Rastogi P;Rabaglio-Poretti M;Lemieux J;Thompson AM;Rea DW;Stambolic V;

More >>

A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.

J Clin Oncol 39, 2021
Ahluwalia M;Parmar A;Chen EX;Jonker DJ;Loree JM;O'Callaghan CJ;Mittman N;Cheung MC;Feilotter H;Monzon JG;Ng DM;Elfiki TA;Hammad N;Lemay F;Tremblay A;Hubay S;Lenehan JG;Salim M;Tu D;Chan KK;

More >>

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

J Clin Oncol 39, 2021
Allaf ME;Kim SE;Master VA;McDermott DF;Signoretti S;Cella D;Gupta RT;Cole S;Shuch BM;Lara PLN;Kapoor A;Chin Heng DY;Leibovich BC;Michaelson MD;Choueiri TK;Jewett MAS;Maskens D;Harshman LC;Carducci MA;Haas NB;

More >>

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

J Clin Oncol 39, 2021
Renouf DJ;Loree JM;Knox JJ;Kavan P;Jonker DJ;Welch S;Couture F;Lemay F;Tehfe M;Harb M;Aucoin N;Ko Y;Tang PA;Topham JT;Jia S;Du P;Schaeffer DF;Gill S;Tu D;O'Callaghan CJ;

More >>

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).Add to Collection

J Clin Oncol 39, 2021
Morris VK;Yothers G;Kopetz S;Jacobs SA;Lucas PC;Iqbal A;Boland PM;Deming DA;Scott AJ;Lim HJ;Wolmark N;George TJ;

More >>